Studies on inhibition of crystallization and in vitro percutaneous absorption of tetramethylpyrazine transdermal delivery system

Chinese Pharmaceutical Journal

Volumn 41, Issue 21, 2006, Pages 1642-1646

  Qiu, Lin ^a   Wang, Qing ^a   Zhang, Jian ^a   Huo, Ning Bo ^a  

^a DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Crystallization; Patch; Polyacrylate adhesive; Tetramethylpyrazine; Transcutol

Indexed keywords

DIETHYLENE GLYCOL MONOETHYL ETHER; POLYACRYLIC ACID; TETRAMETHYLPYRAZINE;

ANIMAL EXPERIMENT; ARTICLE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG INHIBITION; IN VITRO STUDY; NONHUMAN; RAT;

EID: 33845425678     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. HUANG P, LI X H, ZHANG H, et al. Pharmacokinetics and bioequivalence of ligustazine phosphate pills in healthy volunteer [J]. Chin J Clin Pharmacol, 2005, 21(6):445-448.
2. YU Y, GAO Q. Pharmacokinetics of ligustazine [J]. Liaoning J Tradt Chin Med, 2003,30(8):670-671.
3. WENG W Y, XU H N. Study on transdermal permeability of tetramethylpyrazine [J]. Acta Acad Med Shanghai, 1999,26(5):336-341.
4. BAKER R W, LONSDALE H K. Controlled Release of Biologically Active Agents[M]. Vol1. New York: Plenum Press, 1974:25-26.
5. ZHU S S. New Type of Drug [M]. Vol1. Beijing: Chemical Industry Press,2003:312.
6. KOTIYAN P N, VAVIA P R. Eudragits: Role as stallization inhibitors in drug in adhesive transdermal systems of estradiol[J]. Eur J Pharm Biopharm,2001,(52):173-180.
7. FRANCESCO C, PAOLA M, ANTONELLA C, et al. Polymethacrylates as crystallization inhibitors in monolayer transdermal patches containing ibuprofen[J]. Eur J Pharm Biopharm,2005,(60):61-66.
8. WANG Q, TOMOHIRO H, KAKUJI T. Skin penetration enhancement by the synergistic effect of supersaturated dissolution and enhancers [J]. J Chem Eng Jpn,2003,36(1):92-97.
9. KIM J H, CHOI H K. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix [J]. Int J Pharm, 2002,(236):81-85.
10. KARING K, SOPHIE-DOROTHEE C. Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone)polymers[J]. J Pharm Sci,2000,89(10):1325-1334.
11. MA X H, TAW J, CHINAN C M. Control of drug crystallization in transdermal matrix system[J]. Int J Pharm,1996,(142):115-119.
12. QI X H, CHRISITA A, SUN D X, et al. Physicochemical characterization and percutaneous delivery of 2,3,5,6-tetramethylpyrazine[J]. Int J Pharm,2003,253(1):177-183.
13. SHENG T, XU H N, WENG W Y, et al. Preparation of transdermal delivery system containing tetramethylpyrazine Dissociate alkali: China,021576939[P]. 2004-07-07.